CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-14 | Goldan Keith A. Chief Financial Officer | Purchase | +1,250 | $20.03 | $25K | 52,623 |
| 2024-05-15 | Rizo Aleksandra Director | Grant or award · Stock Options (Right to buy) | +35,000 | 35,000 | ||
| 2024-02-07 | Metzger Michael A Chief Executive Officer | Grant or award | +107,250 | 124,909 | ||
| 2024-02-07 | Metzger Michael A Chief Executive Officer | Grant or award | +39,000 | 163,909 | ||
| 2024-02-07 | Metzger Michael A Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +214,500 | $22.28 | $4.8M | 214,500 |
| 2024-02-07 | Goldan Keith A. Chief Financial Officer | Grant or award | +35,000 | 39,673 | ||
| 2024-02-07 | Goldan Keith A. Chief Financial Officer | Grant or award | +11,700 | 51,373 | ||
| 2024-02-07 | Goldan Keith A. Chief Financial Officer | Grant or award · Stock Options (Right to buy) | +70,000 | $22.28 | $1.6M | 70,000 |
| 2024-02-07 | Gallagher Neil President, Head of R&D | Grant or award | +34,688 | 34,688 | ||
| 2024-02-07 | Gallagher Neil President, Head of R&D | Grant or award | +13,125 | 47,813 | ||
| 2024-02-07 | Gallagher Neil President, Head of R&D | Grant or award · Stock Options (Right to buy) | +69,375 | $22.28 | $1.5M | 69,375 |
| 2024-02-07 | Huber Martin H. Jr. Director | Grant or award | +17,000 | 49,000 | ||
| 2024-02-07 | Jarrett Jennifer Director | Grant or award | +17,000 | 65,000 | ||
| 2024-02-07 | Katkin Keith Director | Grant or award | +17,000 | 65,000 | ||
| 2024-02-07 | Meury William Director | Grant or award | +17,000 | 65,000 | ||
| 2024-02-07 | Morrison Briggs Director | Grant or award | +17,000 | 34,836 | ||
| 2024-02-07 | Podlesak Dennis Director | Grant or award | +34,000 | 141,763 | ||
| 2024-02-07 | Legault Pierre Director | Grant or award | +17,000 | 65,000 | ||
| 2024-01-31 | Goldan Keith A. Chief Financial Officer | Other acquisition | +1,183 | $17.42 | $21K | 4,673 |
| 2023-08-09 | Morrison Briggs Director | Option exercise 10b5-1 | +52,855 | $8.77 | $464K | 70,691 |
Page 5 of 15 · 290 trades